These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

136 related items for PubMed ID: 34411389

  • 1. Poor response to intravenous immunoglobulin in patients with a parental history of Kawasaki disease.
    Iwasa M, Inukai S.
    Pediatr Int; 2022 Jan; 64(1):e14963. PubMed ID: 34411389
    [Abstract] [Full Text] [Related]

  • 2. Importance of C-reactive protein level in predicting non-response to additional intravenous immunoglobulin treatment in children with Kawasaki disease: a retrospective study.
    Iwashima S, Kimura M, Ishikawa T, Ohzeki T.
    Clin Drug Investig; 2011 Jan; 31(3):191-9. PubMed ID: 21456105
    [Abstract] [Full Text] [Related]

  • 3. New predictors to identify severe cases during intravenous immunoglobulin therapy in Kawasaki disease.
    Iwasa M, Inukai S.
    Pediatr Int; 2022 Jan; 64(1):e15142. PubMed ID: 35522824
    [Abstract] [Full Text] [Related]

  • 4. Kawasaki disease in Turkish children: a single center experience with emphasis on intravenous immunoglobulin resistance and giant coronary aneurysms.
    Yılmazer MM, Özdemir R, Meşe T, Küçük M, Öner T, Devrim İ, Bayram N, Güven B, Tavlı V.
    Turk J Pediatr; 2019 Jan; 61(5):648-656. PubMed ID: 32104995
    [Abstract] [Full Text] [Related]

  • 5. Prediction of repeated intravenous immunoglobulin resistance in children with Kawasaki disease.
    Lu Y, Chen T, Wen Y, Si F, Wu X, Yang Y.
    BMC Pediatr; 2021 Sep 16; 21(1):406. PubMed ID: 34530763
    [Abstract] [Full Text] [Related]

  • 6. Inflammatory cytokines as predictors of resistance to intravenous immunoglobulin therapy in Kawasaki disease patients.
    Sato S, Kawashima H, Kashiwagi Y, Hoshika A.
    Int J Rheum Dis; 2013 Apr 16; 16(2):168-72. PubMed ID: 23773640
    [Abstract] [Full Text] [Related]

  • 7. Delayed intravenous immunoglobulin treatment increased the risk of coronary artery lesions in children with Kawasaki disease at different status.
    Qiu H, He Y, Rong X, Ren Y, Pan L, Chu M, Wu R, Shi H.
    Postgrad Med; 2018 May 16; 130(4):442-447. PubMed ID: 29745742
    [Abstract] [Full Text] [Related]

  • 8. Predictive value of C-reactive protein to albumin ratio as a biomarker for initial and repeated intravenous immunoglobulin resistance in a large cohort of Kawasaki disease patients: a prospective cohort study.
    Liu X, Wang L, Zhou K, Shao S, Hua Y, Wu M, Liu L, Wang C.
    Pediatr Rheumatol Online J; 2021 Mar 12; 19(1):24. PubMed ID: 33712036
    [Abstract] [Full Text] [Related]

  • 9. A Retrospective Cohort Study of Intravenous Immunoglobulin Therapy in the Acute Phase of Kawasaki Disease: The Earlier, the Better?
    Li W, He X, Zhang L, Wang Z, Wang Y, Lin H, Yuan J, Xie X, Qin Y, Huang P.
    Cardiovasc Ther; 2021 Mar 12; 2021():6660407. PubMed ID: 34239607
    [Abstract] [Full Text] [Related]

  • 10. High-Dose Aspirin is Associated with Anemia and Does Not Confer Benefit to Disease Outcomes in Kawasaki Disease.
    Kuo HC, Lo MH, Hsieh KS, Guo MM, Huang YH.
    PLoS One; 2015 Mar 12; 10(12):e0144603. PubMed ID: 26658843
    [Abstract] [Full Text] [Related]

  • 11. Unique Molecular Patterns Uncovered in Kawasaki Disease Patients with Elevated Serum Gamma Glutamyl Transferase Levels: Implications for Intravenous Immunoglobulin Responsiveness.
    Wang Y, Li Z, Hu G, Hao S, Deng X, Huang M, Ren M, Jiang X, Kanegaye JT, Ha KS, Lee J, Li X, Jiang X, Yu Y, Tremoulet AH, Burns JC, Whitin JC, Shin AY, Sylvester KG, McElhinney DB, Cohen HJ, Ling XB, Pediatric Emergency Medicine Kawasaki Disease Research Group.
    PLoS One; 2016 Mar 12; 11(12):e0167434. PubMed ID: 28002448
    [Abstract] [Full Text] [Related]

  • 12. Infliximab Plus Intravenous Immunoglobulin (IVIG) Versus IVIG Alone as Initial Therapy in Children With Kawasaki Disease Presenting With Coronary Artery Lesions: Is Dual Therapy More Effective?
    Jone PN, Anderson MS, Mulvahill MJ, Heizer H, Glodé MP, Dominguez SR.
    Pediatr Infect Dis J; 2018 Oct 12; 37(10):976-980. PubMed ID: 29461447
    [Abstract] [Full Text] [Related]

  • 13. Clinical symptoms of patients with Kawasaki disease include smoldering fever.
    Iwasa M, Inukai S.
    Pediatr Int; 2023 Oct 12; 65(1):e15541. PubMed ID: 36975765
    [Abstract] [Full Text] [Related]

  • 14. The time option of IVIG treatment is associated with therapeutic responsiveness and coronary artery abnormalities but not with clinical classification in the acute episode of Kawasaki disease.
    Samadli S, Liu FF, Mammadov G, Wang JJ, Liu HH, Wu YF, Luo HH, Wu Y, Chen WX, Zhang DD, Wei W, Hu P.
    Pediatr Rheumatol Online J; 2019 Jul 31; 17(1):53. PubMed ID: 31366406
    [Abstract] [Full Text] [Related]

  • 15. Analysis of potential risk factors associated with nonresponse to initial intravenous immunoglobulin treatment among Kawasaki disease patients in Japan.
    Uehara R, Belay ED, Maddox RA, Holman RC, Nakamura Y, Yashiro M, Oki I, Ogino H, Schonberger LB, Yanagawa H.
    Pediatr Infect Dis J; 2008 Feb 31; 27(2):155-60. PubMed ID: 18174868
    [Abstract] [Full Text] [Related]

  • 16. The effects of early intravenous immunoglobulin therapy for Kawasaki disease: The 22nd nationwide survey in Japan.
    Kuwabara M, Yashiro M, Ae R, Yanagawa H, Nakamura Y.
    Int J Cardiol; 2018 Oct 15; 269():334-338. PubMed ID: 30049499
    [Abstract] [Full Text] [Related]

  • 17. A Comprehensive Assessment of the Value of Laboratory Indices in Diagnosing Kawasaki Disease.
    Ye Q, Shao WX, Shang SQ, Zhang T, Hu J, Zhang CC.
    Arthritis Rheumatol; 2015 Jul 15; 67(7):1943-50. PubMed ID: 25778686
    [Abstract] [Full Text] [Related]

  • 18. Intravenous Immunoglobulin Gamma (IVIG) versus IVIG Plus Infliximab in Young Children with Kawasaki Disease.
    Han CL, Zhao SL.
    Med Sci Monit; 2018 Oct 11; 24():7264-7270. PubMed ID: 30307902
    [Abstract] [Full Text] [Related]

  • 19. Prediction of intravenous immunoglobulin resistance in patients with Kawasaki disease according to the duration of illness prior to treatment.
    Ha KS, Lee J, Lee KC.
    Eur J Pediatr; 2020 Feb 11; 179(2):257-264. PubMed ID: 31713683
    [Abstract] [Full Text] [Related]

  • 20. Therapeutic Window of Intravenous Immunoglobulin (IVIG) and its correlation with IVIG-resistant in Kawasaki Disease: a retrospective study.
    Cai JH, Tang M, Zhang HX, Dan Luo E, Zhang R, Shuai SP, Liang H, Tao WJ, Wu MJ, Wen Y, Yang YF.
    J Pediatr (Rio J); 2023 Feb 11; 99(2):161-167. PubMed ID: 35995125
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.